Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Touchlight Genetics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2016

Posted on: 07 Oct 16

London, UK, 7th October 2016 / Sciad NewswireSynbiCITE congratulates Touchlight Genetics as the winner of Best Emerging UK Synthetic Biotech Company at the OBN’s 8th Annual Awards Ceremony held last night. The OBN Awards celebrate innovation and achievement across the UK life sciences industry, including emerging to late stage R&D companies as well as life science investors.

Touchlight Genetics, a London-based biotechnology company, has successfully established and patented a revolutionary enzymatic process of DNA amplification. Their success at the OBN Awards was attributed to the development of an innovative, in vitro dual enzyme process, capable of producing DNA at commercial scale and quality.

In sponsoring this award, we are supporting the growth of the UK’s burgeoning synthetic biology industry, a core aim of SynbiCITE.

The 3 finalist companies under consideration for this award were:

  • Chain Biotech
  • Green Biologics 
  • Touchlight Genetics


About SynbiCITE
SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE and partners across the UK and globally are committed to developing this technology through responsible innovation which encompasses ethical, societal and environmental considerations. SynbiCITE is focused at Imperial College London and is - with partners from industry, academia and organisations that help develop business growth - accelerating the commercialisation of world-class science and the emerging technologies encompassed by synthetic biology into new products, tools, processes and services. SynbiCITE is growing UK industry in the sector and improving synthetic biology innovation, using industry to achieve significant economic impact, generate wealth for the companies, generate skilled workers and create jobs.

Editor's Details

Emma Pickup

Last updated on: 07/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.